888 related articles for article (PubMed ID: 2208789)
21. Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effectors and progenitors into NK- and T-like cells.
Kalland T; Belfrage H; Bhiladvala P; Hedlund G
J Immunol; 1987 Jun; 138(11):3640-5. PubMed ID: 3495566
[TBL] [Abstract][Full Text] [Related]
22. IL-4 regulation of murine lymphokine-activated killer activity in vitro. Effects on the IL-2-induced expansion, cytotoxicity, and phenotype of lymphokine-activated killer effectors.
Mulé JJ; Krosnick JA; Rosenberg SA
J Immunol; 1989 Jan; 142(2):726-33. PubMed ID: 2783444
[TBL] [Abstract][Full Text] [Related]
23. Lymphokine-activated killer cells in rats. IV. Developmental relationships among large agranular lymphocytes, large granular lymphocytes, and lymphokine-activated killer cells.
Maghazachi AA; Vujanovic NL; Herberman RB; Hiserodt JC
J Immunol; 1988 Apr; 140(8):2846-52. PubMed ID: 3258622
[TBL] [Abstract][Full Text] [Related]
24. IL-4 inhibits IL-2 induction of LAK cytotoxicity in lymphocytes from a variety of lymphoid tissues.
Colquhoun SD; Economou JS; Shau H; Golub SH
J Surg Res; 1993 Nov; 55(5):486-92. PubMed ID: 8231167
[TBL] [Abstract][Full Text] [Related]
25. A functional and phenotypic comparison of murine natural killer (NK) cells and lymphokine-activated killer (LAK) cells.
Hoskin DW; Stankova J; Anderson SK; Roder JC
Int J Cancer; 1989 May; 43(5):940-8. PubMed ID: 2469657
[TBL] [Abstract][Full Text] [Related]
26. The mechanism of IL-2-mediated protection against GVHD in mice. II. Protection occurs independently of NK/LAK cells.
Sykes M; Abraham VS
Transplantation; 1992 May; 53(5):1063-70. PubMed ID: 1533968
[TBL] [Abstract][Full Text] [Related]
27. Prostaglandin E2-mediated inactivation of various killer lineage cells by tumor-bearing host macrophages.
Parhar RS; Lala PK
J Leukoc Biol; 1988 Dec; 44(6):474-84. PubMed ID: 2973508
[TBL] [Abstract][Full Text] [Related]
28. Interactive effects of alpha-interferon A/D and interleukin 2 on murine lymphokine-activated killer activity: analysis at the effector and precursor level.
Chikkala NF; Lewis I; Ulchaker J; Stanley J; Tubbs R; Finke JH
Cancer Res; 1990 Feb; 50(4):1176-82. PubMed ID: 2297766
[TBL] [Abstract][Full Text] [Related]
29. Lysis of human malignant mesothelioma cells by natural killer (NK) and lymphokine-activated killer (LAK) cells.
Manning LS; Bowman RV; Darby SB; Robinson BW
Am Rev Respir Dis; 1989 Jun; 139(6):1369-74. PubMed ID: 2786360
[TBL] [Abstract][Full Text] [Related]
30. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
[TBL] [Abstract][Full Text] [Related]
31. In vivo administration of low-dose human interleukin-2 induces lymphokine-activated killer cells for enhanced cytolysis in vitro.
Hancock GE; Molloy A; Ab BK; Kiessling R; Becx-Bleumink M; Cohn ZA; Kaplan G
Cell Immunol; 1991 Feb; 132(2):277-84. PubMed ID: 1988157
[TBL] [Abstract][Full Text] [Related]
32. Role of prolactin in the modulation of NK and LAK cell activity after short- or long-term morphine administration in neoplastic patients.
Provinciali M; Di Stefano G; Stronati S; Raffaeli W; Pari G; Fabris N
Int J Immunopharmacol; 1996 Oct; 18(10):577-86. PubMed ID: 9080251
[TBL] [Abstract][Full Text] [Related]
33. Lymphokine-activated killer cells in rats: analysis of tissue and strain distribution, ontogeny, and target specificity.
Vujanovic NL; Herberman RB; Hiserodt JC
Cancer Res; 1988 Feb; 48(4):878-83. PubMed ID: 3257411
[TBL] [Abstract][Full Text] [Related]
34. Induction of lymphokine-activated killer (LAK) activity in canine lymphocytes with low dose human recombinant interleukin-2 in vitro.
Helfand SC; Soergel SA; Modiano JF; Hank JA; Sondel PM
Cancer Biother; 1994; 9(3):237-44. PubMed ID: 7820185
[TBL] [Abstract][Full Text] [Related]
35. Gelatin sponge model of effector recruitment: tumoricidal activity of adherent and non-adherent lymphokine-activated killer cells after culture in interleukin-2.
Akporiaye ET; Barbieri CA; Stewart CC; Bender JG
J Leukoc Biol; 1991 Feb; 49(2):189-96. PubMed ID: 1991999
[TBL] [Abstract][Full Text] [Related]
36. Defective natural immunity: an early manifestation of human immunodeficiency virus infection.
Ullum H; Gøtzsche PC; Victor J; Dickmeiss E; Skinhøj P; Pedersen BK
J Exp Med; 1995 Sep; 182(3):789-99. PubMed ID: 7650485
[TBL] [Abstract][Full Text] [Related]
37. Heterogeneity of lymphokine-activated killer cells induced by IL-2. Separate lymphoid subpopulations lyse tumor, allogeneic blasts, and modified syngeneic blasts.
LeFor AT; Eisenthal A; Rosenberg SA
J Immunol; 1988 Jun; 140(11):4062-9. PubMed ID: 3259603
[TBL] [Abstract][Full Text] [Related]
38. P-glycoprotein-mediated multidrug resistance and lymphokine-activated killer cell susceptibility in ovarian carcinoma.
Savas B; Cole SP; Tsuruo T; Pross HF
J Clin Immunol; 1996 Nov; 16(6):348-57. PubMed ID: 8946280
[TBL] [Abstract][Full Text] [Related]
39. Induction of human lymphokine-activated killer cells by IFN-alpha and IFN-gamma.
Ellis TM; McKenzie RS; Simms PE; Helfrich BA; Fisher RI
J Immunol; 1989 Dec; 143(12):4282-6. PubMed ID: 2512355
[TBL] [Abstract][Full Text] [Related]
40. Ethanol consumption reduces the cytolytic activity of lymphokine-activated killer cells.
Gallucci RM; Meadows GG
Alcohol Clin Exp Res; 1995 Apr; 19(2):402-9. PubMed ID: 7625574
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
